Profile

Cover photo
Senesco Technologies, Inc.
4 followers|5,093 views
AboutPostsPhotosVideos

Stream

 
The ALS Ice Bucket Challenge has increased awareness of patient advocacy around the world. Find out how you can become a Lymphoma Research Foundation advocate and the many ways you can make a difference in the lymphoma community. http://bit.ly/1C71AmC
1
Add a comment...
 
Senesco Closes Enrollment in Its Phase 1b/2a SNS01-T Study
http://bit.ly/1u5tg61
1
Add a comment...
 
Researchers at the University of Oslo have developed a new statistical method to determine at an early stage of lymphoma treatment which patients will develop an aggressive variant and when it will occur. This determination will allow doctors to initiate treatment early, or avoid burdensome treatment for those not at risk. http://bit.ly/1C70JCw
1
Add a comment...
 
From his Houston Texans teammates and National Football League opponents to family members and fans, David Quessenberry has countless allies in his fight against non-Hodgkin’s lymphoma. “It’s overwhelming, and it motivates me to fight my fight even harder,” Quessenberry told http://on.today.com/yayDFJ. “I wake up every day knowing that I have an army behind me.” Read more here: http://on.today.com/1BC0LC6
1
Add a comment...
 
Phillip Tallmadge was 20 years old when he passed away from stage 1 Non-Hodgkins Lymphoma, less than 16 months after he was diagnosed. Throughout his illness, he posted updates on Facebook which left a lasting impression on his family and friends. After his passing, his brother shared Phillip's one last wish, encouraging his community to send flowers to someone simply out of kindness. The community reaction was overwhelming. Read the full article here: http://bit.ly/1BbuWA0
A young North Tonawanda resident who inspired his community while he courageously battled cancer is still bettering other people’s lives — even after
1
Add a comment...
 
Non-Hodgkin's lymphoma generally involves the presence of cancerous lymphocytes in your lymph nodes, but the disease can also spread to other parts of your lymphatic system. Learn more about Non-Hodgkin's lymphoma here: http://mayocl.in/1sach1f
1
Add a comment...
Have them in circles
4 people
Liz Peters's profile photo
Christina Kindborg's profile photo
Katherine Johnston's profile photo
Frank LaSaracina's profile photo
 
The diagnosis of multiple myeloma is often made incidentally during routine blood tests for other conditions. Learn more about diagnosing myeloma from the Multiple Myeloma Research Foundation here: http://bit.ly/1C71gV2
1
Add a comment...
 
Tom Brokaw will be honored with the Spirit of Hope Award at the Multiple Myeloma Research Foundation annual gala. Brokaw was diagnosed with multiple myeloma in August of 2013. http://bit.ly/1u0V2AD
1
Add a comment...
 
Doctors will perform many tests when Non-Hodgkin's Lymphoma is suspected. Learn about the plan of action here: http://bit.ly/1sO2XR2
1
Add a comment...
 
Roche (ROG.VX), a biotech Company developing treatment options for breast, skin, colon, ovarian, lung and numerous other cancers announced on Monday that it will acquire Santaris Pharma, a privately-held Danish biotech company for up to $450 million in cash. Santaris develops drugs which work by blocking or "silencing" microRNAs, tiny strands of RNA, or ribonucleic acid, that help turn genes into proteins. This acquisition is an indication of a growing interest and confidence in siRNA-based drugs. http://reut.rs/1BbuSQP
ZURICH (Reuters) - Roche <ROG.VX> said on Monday it will buy Santaris Pharma, a privately-held Danish biotech company that has developed a new designer molecule, for up to $450 million in cash.Santaris,
1
Add a comment...
 
A study by the American Society for Reproductive Medicine, published in the journal Fertility and Sterility, showed treatment using combination chemotherapy, with or without radiation for both Hodgkin's and non-Hodgkin's lymphoma can harm or halt sperm production. "It is imperative that prior to the initiation of therapy, counselling and sperm preservation be made available to all lymphoma patients and their partners who may want to have children in the future," stated Dr. Rebecca Sokol, President of the American Society for Reproductive Medicine. For more information, read the full article here: http://bit.ly/1ARtbI3
1
Add a comment...
People
Have them in circles
4 people
Liz Peters's profile photo
Christina Kindborg's profile photo
Katherine Johnston's profile photo
Frank LaSaracina's profile photo
Links
Story
Tagline
Senesco Technologies (SNTID) is a clinical-stage biotech company specializing in cancer therapeutics. Its proprietary gene regulation technology has demonstrated the ability to eliminate cancerous cells and protect healthy cells from premature death.
Introduction

Senesco is currently in a phase 1b/2a trial with a product that treats B-cell cancers, which include multiple myeloma, chronic lymphocytic leukemia, and non-Hodgkin’s B-cell lymphomas. The technology was developed over the last 15 years through the discovery that the genetic pathway for cell growth control is common to both plants and humans.